Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors
Authors:
Open Access
- 11 April 2024
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 174, 116565
Abstract
No abstract availableKeywords
Funding Information
- National Major Science and Technology Projects of China (2019ZX09201001)
- National Natural Science Foundation of China (81773621)
- National Natural Science Foundation of China (82073751)
This publication has 54 references indexed in Scilit:
- Epcoritamab: First ApprovalDrugs, 2023
- Glofitamab: First ApprovalDrugs, 2023
- Teclistamab: First ApprovalDrugs, 2022
- Mosunetuzumab: First ApprovalDrugs, 2022
- Tebentafusp: First ApprovalDrugs, 2022
- Bioprocess development of a stable FUT8−/−-CHO cell line to produce defucosylated anti-HER2 antibodyBioprocess and Biosystems Engineering, 2019
- Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make BiobettersBioDrugs, 2015
- Blinatumomab: First Global ApprovalDrugs, 2015
- Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer modelEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Production and characterization of a mouse/human chimeric antibody directed against human neuroblastomaInternational Journal of Cancer, 1993